Nitroglycerin CR 6.4mg Cardiac PCD Pharma Franchise

Brand Name

NITROGINA 6.4 Tablet

Composition

Nitroglycerin Controlled Released 6.4mg

Therapeutic Use

Management of angina pectoris

Size

30Tab

Verified Exporter

Verified Seller

Trusted Pharma

Description

Nitroglycerin 6.4mg Tablet contains Nitroglycerin Controlled Release 6.4 mg, an organic nitrate vasodilator used for the prevention of angina pectoris in selected patients when prescribed by a qualified healthcare professional. Nitroglycerin relaxes vascular smooth muscle, widens blood vessels and reduces the workload of the heart. The controlled-release formulation is designed to release the medicine over time; its precise release characteristics should be verified against the approved product information.

Nitroglycerin controlled-release Tablets may be prescribed for ongoing angina prevention in patients with coronary artery disease when nitrate therapy is appropriate. They should not be assumed to provide the rapid relief required during a sudden angina attack. Patients should follow their clinician’s instructions for managing acute chest pain and seek emergency care for severe, new or persistent symptoms.

CardianCare focuses on cardiac and diabetic healthcare products for doctors, pharmacists, procurement teams and pharmaceutical business partners. Businesses searching for a Nitroglycerin 6.4mg Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing-source details and relevant quality documentation.

For pharmaceutical procurement teams evaluating a Nitroglycerin 6.4mg Tablets manufacturer and supplier India, important considerations include the composition, strength, release profile, product authorization, packaging, batch traceability, shelf life and storage requirements.

2. Key Ingredients

Composition: Nitroglycerin Controlled Release 6.4 mg

Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate classified as a vasodilator. Through nitric oxide-related signalling, it increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, promoting relaxation and dilation of blood vessels.

Its main haemodynamic effect is venous dilation, which reduces venous return to the heart, lowers cardiac preload and decreases myocardial oxygen demand. These actions can help prevent angina symptoms in appropriately selected patients.

The controlled-release design aims to provide medicine release over time. The 6.4 mg strength and release profile should be verified against the approved product label, as different nitroglycerin formulations are not automatically interchangeable.

Businesses researching a Nitroglycerin 6.4mg pharmaceutical company India should review the product’s approved formulation, release characteristics, labelling, regulatory status and applicable quality documentation.

Companies evaluating a Nitroglycerin 6.4mg medicine manufacturer India should verify the legal manufacturer, product authorization, batch documentation and relevant quality standards before procurement.

3. Key Benefits

Angina prevention: May help prevent angina episodes in appropriately selected patients when prescribed for ongoing management.

Reduced cardiac workload: Venous dilation can reduce the amount of blood returning to the heart, lowering cardiac preload.

Lower myocardial oxygen demand: Reduced cardiac workload can decrease the heart muscle’s oxygen requirements.

Controlled-release presentation: Provides a controlled-release dosage form intended for use according to the approved prescribing instructions.

Support for individualized cardiovascular care: May be included in a broader coronary artery disease treatment plan when clinically appropriate.

established nitrate mechanism: Uses the vasodilator action of nitroglycerin to support preventive angina management.

The clinical response varies between patients. Controlled-release nitroglycerin does not cure coronary artery disease and should not replace other prescribed cardiovascular treatments or risk-reduction measures.

Pharmaceutical buyers searching for a Nitroglycerin 6.4mg supplier India should verify product authenticity, approved specifications, availability, shelf life and supporting documentation.

A Nitroglycerin 6.4mg Tablet wholesaler and distributor India enquiry may include stock availability, minimum order quantities, delivery coverage, licensing requirements and applicable commercial terms.

Businesses seeking a Nitroglycerin 6.4mg bulk supplier India should request a formal quotation and confirm packaging specifications, storage conditions, batch traceability and quality documentation.

A Nitroglycerin 6.4mg pharmaceutical distributor India should verify distribution eligibility, product authorization and approved product information before starting commercial activities.

4. How Does It Work?

Nitroglycerin acts as a nitrate vasodilator. Its bioactivation promotes nitric oxide-related signalling and increases cGMP within vascular smooth muscle, leading to relaxation of blood vessel walls.

The principal effect is venous dilation. This reduces venous return to the heart and lowers the amount of work the heart must perform, thereby decreasing myocardial oxygen demand. Coronary vasodilation may also contribute to its antianginal effects.

The controlled-release formulation is intended to release nitroglycerin over time. Its dose and schedule must follow the approved product information. Nitrate tolerance may develop with continuous exposure, so any dosing schedule or nitrate-free interval must be determined by the prescriber rather than adjusted independently.

5. Directions for Use

Dosage: Take only as prescribed by a qualified doctor. The appropriate dose and schedule depend on the patient’s condition and the approved formulation.

Administration: Follow the product label for instructions on taking the controlled-release Tablet. Do not crush, chew or split it unless the approved instructions explicitly permit this.

Regular timing: Follow the prescribed schedule consistently. Do not change the dose or timing without medical advice.

Acute chest pain: Do not assume this controlled-release Tablet will provide rapid relief during a sudden angina attack. Follow the emergency plan provided by the treating clinician.

Missed dose: Follow the patient information leaflet or ask a doctor or pharmacist. Do not take a double dose to compensate for a missed dose.

Alcohol: Discuss alcohol use with the doctor, as it may worsen dizziness and low blood pressure.

Monitoring: Attend recommended follow-up appointments and report fainting, severe dizziness or worsening chest pain.

Do not stop or modify treatment without consulting the prescriber. New, severe or persistent chest pain, especially with breathlessness, sweating, nausea or faintness, requires emergency medical assessment.

6. Possible Side Effects

Possible side effects include:

Headache

Dizziness or light-headedness

Flushing

Low blood pressure

Weakness

Nausea

Reflex increase in heart rate

Important adverse reactions

Severe hypotension: Marked dizziness, fainting or collapse requires urgent assessment.

Worsening chest pain: New or worsening chest pain needs prompt medical evaluation.

Persistent or severe headache: Discuss severe or unusual symptoms with a healthcare professional, particularly if other warning signs occur.

Rare serious reactions: Serious allergic reactions or methemoglobinaemia are uncommon but require urgent medical attention if suspected.

Side effects may be more likely when nitroglycerin is combined with other blood-pressure-lowering medicines or alcohol. This list is not exhaustive; consult a healthcare professional about persistent or concerning symptoms.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Contraindications and interactions: Nitroglycerin must not be used with phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil, tadalafil or vardenafil, or with riociguat, because these combinations can cause a dangerous fall in blood pressure. Follow all contraindications in the approved product information.

Low blood pressure: Use requires careful assessment in patients with hypotension, volume depletion or a tendency to faint.

Cardiovascular conditions: Patients with certain conditions, including severe anaemia, raised intracranial pressure or specific forms of shock, require specialist assessment and may have contraindications to nitrate therapy.

Liver and kidney health: Inform the doctor about liver or kidney disease and follow the product-specific prescribing guidance.

Pregnancy: Use during pregnancy only when a clinician determines that it is necessary after assessing the potential benefits and risks.

Breastfeeding: Seek medical advice before use while breastfeeding.

Drug interactions: Tell the doctor about all medicines and supplements, especially PDE-5 inhibitors, riociguat, antihypertensives and other vasodilators. Alcohol can intensify blood-pressure-lowering effects.

Driving and machinery: Avoid driving or operating machinery if dizziness, blurred vision or light-headedness occurs.

Storage: Store in the original packaging according to the approved product label, away from excessive heat and moisture and out of children’s reach.

This information is educational and does not replace approved prescribing information or individualized medical advice.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products and provides a contact point for pharmaceutical trade enquiries. Doctors, pharmacists, procurement teams, wholesalers, distributors and eligible business partners can contact the company to enquire about current product availability and applicable commercial arrangements.

Businesses researching a Nitroglycerin 6.4mg PCD pharma franchise India opportunity should confirm directly whether the product and relevant programme are available, including territory eligibility, partner requirements and applicable commercial terms.

For a Nitroglycerin 6.4mg Tablets PCD pharma franchise enquiry, prospective partners can request information about product availability, minimum order quantities, licensing requirements, distribution eligibility and any applicable promotional support.

Companies exploring a Nitroglycerin 6.4mg Tablet PCD franchise should verify programme availability and product eligibility before making investment or promotional commitments.

Businesses evaluating Nitroglycerin 6.4mg third party manufacturing India services should first confirm whether the proposed company offers these arrangements. Due diligence should include manufacturing authorization, applicable GMP compliance, product approvals, controlled-release formulation capabilities and quality documentation.

A Nitroglycerin 6.4mg Tablet third party manufacturer India enquiry should cover the facility’s regulatory status, release-profile specifications, quality systems, batch-release procedures, packaging requirements and contractual responsibilities.

Companies investigating Nitroglycerin 6.4mg contract manufacturing India should confirm service availability and discuss formulation specifications, technical documentation, quality agreements, regulatory responsibilities and commercial feasibility with the proposed manufacturing partner.

Contact CardianCare through its official website to enquire about current product availability, pharmaceutical distribution opportunities and applicable business arrangements. PCD franchise, third-party manufacturing and contract manufacturing services must be confirmed directly before being represented as available.

9. For More Information

For more information about NITROGINA 6.4mg Tablet (Nitroglycerin Controlled Release 6.4 mg), click here

Frequently Asked Questions

It may be prescribed to help prevent angina episodes in selected patients with coronary artery disease. The precise indication depends on the approved product information and the treating clinician's assessment.

The supplied composition is Nitroglycerin Controlled Release 6.4 mg. Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate vasodilator.

It promotes vascular smooth muscle relaxation through nitric oxide-related signalling. This widens blood vessels, reduces venous return to the heart and lowers cardiac oxygen demand.

The formulation is designed to release the medicine over time and may support ongoing angina prevention. It should not be assumed to act like a rapid-relief sublingual product.

Take it exactly as prescribed and follow the approved product instructions. Do not crush, chew or split the Tablet unless the official instructions permit it.

Headache, dizziness, flushing, low blood pressure, weakness and nausea can occur. Seek medical advice for persistent symptoms and urgent care for fainting or severe reactions.

Nitroglycerin must not be combined with PDE-5 inhibitors such as sildenafil, tadalafil or vardenafil, or with riociguat, because severe hypotension can result. Discuss all medicines with the prescriber.

Do not assume that a controlled-release Tablet will provide rapid relief during an acute attack. Follow the emergency plan prescribed by the clinician and seek emergency care for severe, new or persistent chest pain.

Store it in its original packaging under the conditions stated on the approved label, protected from excessive heat and moisture and kept out of children's reach.

Verify the composition, strength, controlled-release characteristics, approved dosage form, product authorization, manufacturing source, batch documentation, shelf life, packaging and storage conditions. Confirm distribution or manufacturing services directly with the relevant company.

Reviews

There are no reviews yet.

Be the first to review “Nitroglycerin CR 6.4mg Cardiac PCD Pharma Franchise”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line